

LITERÁRNÍ ZDROJE A DOPORUČENÁ LITERATURA

1. Bailey T, Grunberger G, Bode B, et al. American association of clinical endocrinologists and American college of endocrinology 2016 outpatient glucose monitoring consensus. *Endocrine Pract.* 2016;22:231–60.
2. Beck R, Bergenstal R, Cheng P, et al. The relationships between Time in Range, hyperglycemia metrics, and HbA1c. *J Diabetes Sci Technol.* 2019; Epub DOI: 10.1177/1932296818822496.
3. Beck R, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with type 1 diabetes using insulin injections. The DIAMOND randomised clinical trial. *JAMA.* 2017;317:371–8.
4. Bolderman K. Putting your patients on the pump. Initiation and maintenance guidelines. 2nd ed. American Diabetes Association; 2013.
5. Danne T, Nimri R, Battelino T, et al. International consensus on the use of Continuous Glucose Monitoring. *Diabetes Care.* 2017;40:1631–40.
6. Davidson P, Hebblewhite M, Sled R et al. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate to insulin ratio. *Endocrine Pract.* 2008;14:1095–101.
7. Fonseca V, Grunberger G, Anhalt H, et al. Continuous glucose monitoring: a consensus of the American association of clinical endocrinologists and American college of endocrinology. *Endocrine Pract.* 2016;22:1008–21.
8. Gomez A, Carrillo D, Velandia O, Devices for continuous monitoring of glucose: update in technology. *Med Devices.* 2017;10:215–24.
9. Grunberger G, Handelsman Z, Bloomgarden Z et al. American Association of Clinical Endocrinologists and American College of Endocrinology 2018 Position statement on integration of insulin pumps and continuous glucose monitoring in patients with diabetes mellitus. *Endocrine Pract.* 2018;24:302–8.
10. Hanaire H, Lassman-Vague V, Jeandidier N et al. Treatment of diabetes mellitus using an external insulin pump: the state of art. *Diabetes Metab.* 2008;34:401–23.
11. Hng TM, Burren D. Appearance of Do-It-Yourself closed-loop systems to manage type 1 diabetes. *Intern Med J.* 2018;48:1400–4.
12. Hovorka R. Continuous glucose monitoring and closed-loop systems. *Diabet Med.* 2006;23:1–12.
13. Hussain S, Oliver N. Insulin pumps and continuous glucose monitoring. Made easy. Elsevier; 2016.
14. Jeandidier N, Riveline J, Tubiana-Rufi N, et al. Treatment of diabetes mellitus using an external insulin pump in clinical practice. *Diabetes Metab.* 2008;34:425–38.
15. Jirkovská A. Současné možnosti kontinuální monitorace glykémie u pacientů s diabetem. *Remedia.* 2009;2:94–102.
16. Jirkovská A et al. Jak (si) kontrolovat a zvládat diabetes. Manuál pro edukaci diabetiků. Mladá fronta; 2014.

17. Jirkovská A, Kožnarová R. Samostatná kontrola diabetu a úpravy léčebného režimu. In: Pelikánová T, Bartoš V et al. Praktická diabetologie, 6th ed. Maxdorf; 2018.
18. Kaufman F, Westfall E. Insulin pumps and continuous glucose monitoring. American Diabetes Association. 2017.
19. Klonoff D, Ahn D, Drincic A. Continuous glucose monitoring: a review of the technology and clinical use. *Diabetes Res Clin Pract.* 2017;133:178–92.
20. Knight G. Risks with continuous subcutaneous insulin infusion can be serious. *BMJ.* 2001;323:693–4.
21. Kropij J, Choudhary P, Neupane S, et al. Accuracy and longevity of an implantable Continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial. *Diabetes Care.* 2017;40:63–8.
22. Neumann D, Picková K, Brázdová L. Flexibilní léčba diabetes mellitus 1. typu – Postupy pro MDI a CSII. Mladá Fronta; 2017.
23. Petruželková L, Picková K, Sumnik Z, et al. Effectiveness of SmartGuard Technology in the Prevention of Nocturnal Hypoglycemia After Prolonged Physical Activity. *Diabetes Technol Ther.* 2017;19:299–304.
24. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: metaanalysis of randomised controlled trials. *BMJ.* 2002a;324:1–5.
25. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years. Evidence base for the expanding use of insulin pump therapy in type 1 diabetes. *Diabetes Care.* 2002b;25:593–5.
26. Pickup J, Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of Type 1 and Type 2 diabetes. *Diabetes Care.* 2008;31:S140–S145.
27. Pickup J. Insulin pumps after injections and CGM in T1DM. News and Views. *Nature reviews endocrinology* 2017;www.nature.com/nrendo
28. Piřhová P, Šteřhová K. Léčba inzulinovou pumpou pro praxi. Praha: Geum; 2009.
29. Prázný M. Progress in the development of insulin pumps and their advanced automatic functions. *Vnitr Lek.* 2015;61:355, 357, 359–360.
30. Prázný M, Soupal J. Glycemic variability and continuous monitoring of glycemia. *Vnitr Lek.* 2014;60:757–63.
31. Ruřavý Z, Honěk P, Dušek L et al. Monitoring of diabetes compensation in patients treated with an insulin pump in the Czech Republic. *Vnitr Lek.* 2015; 61(Suppl 3).
32. Ryan E, Holland J, Stroulia E, et al. Improved A1C levels in type 1 diabetes with Smartphone App use. *Ca J Diabetes.* 2017;41:33–40.
33. Scheiner G. Practical CGM. A guide to improving outcomes through Continuous Glucose Monitoring. ADA. 2015.
34. Šoupal J, Petruželková L, Flekač M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. *Diabetes Technol Ther.* 2016;18:532–8.

35. Štechová K. Kontinuální monitorace glykémie jako prostředek k analýze dietních chyb a k dietní edukaci. *Kazuistiky v diabetologii* 2012;10:14–20.
36. Štechová K. *Technologie v diabetologii*. Maxdorf; 2016.
37. Štechova K, Štecha R, Kvapil M. Aviation and technology in diabetes management. *Diabetes Technol Ther*. 2015;17:301–3.
38. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*. 1993;329:977–86.
39. The Diabetes Control and Complications Trial (DCCT) Research Group. The absence of glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. *Diabetes*. 1996;45:1289–98.
40. Vigersky R, Shrivastav M. Role of continuous glucose monitoring for type 2 diabetes management and research. *J Diabetes Complications*. 2017;31:280–7.
41. Wainstein J, Metzger M, Boaz M, et al. Insulin pump therapy vs multiple daily injections in obese type 2 diabetic patients. *Diabet Med*. 2005;22:1037–46.
42. Walsh J, Roberts R, Bailey T. Guidelines for optimal bolus calculator settings in adults. *J Diabetes Sci Technol*. 2011;5:129–35.
43. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. *Lancet*. 2008;371:1753–60.